SAN DIEGO, Feb. 16, 2011 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today the issuance of U.S. Patent No. 7,888,112 covering DNA vaccines for cytomegalovirus (CMV) containing specific gene sequences and formulated with Vical’s Vaxfectin® adjuvant.
